- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May.
Scheduled conference presentations include the following:
TIDES 2014 - Providence, RI, May 12-15
May 12, 2014 - An oral presentation titled, "Using Endosomal Escape Agents for siRNA Delivery in vivo," will be presented at the workshop entitled "In vivo Delivery of Therapeutic Oligonucleotides: Challenges, Considerations and Solutions," by David Lewis, Ph.D., Chief Scientific Officer
May 14, 2014 - An oral presentation titled, "Next Generation Dynamic Polyconjugates for siRNA Delivery in vivo," will be presented by Aaron Almeida, Ph.D., Senior Scientist II
10th International Symposium on Polymer Therapeutics - Valencia, Spain, May 19-21
May 19, 2014 - An oral presentation titled, "Polymer-Based Vehicles for siRNA Delivery in vivo," will be presented by David Rozema, Ph.D., Vice President, Chemistry
ASGCT 17th Annual Meeting - Washington, DC, May 21-24
May 21, 2014 - An oral presentation titled, "Development of an siRNA-Based Therapeutic for Chronic HBV Infection Using DPC Technology," will be presented by David Lewis, Ph.D., Chief Scientific Officer
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to
For more information, please click here
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Martina Schwarzkopf, Ph.D.
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016